{"id":"W58191675","doi":"10.1200/jco.2005.23.16_suppl.5103","title":"A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer therapeutics and mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre","funders":"","keywords":"Medicine; Epirubicin; Irinotecan; Neutropenia; Internal medicine; Nedaplatin; Cervical cancer; Adverse effect; Phases of clinical research; Febrile neutropenia; Response Evaluation Criteria in Solid Tumors; Oncology; Anemia; Chemotherapy; Cisplatin; Common Terminology Criteria for Adverse Events; Cancer; Surgery; Colorectal cancer; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002974915,0.001683686,0.002335399,0.0005115211,0.0006422866,0.0008920906,0.001070346,0.001174698,0.002644579],"category_scores_gemma":[0.00147692,0.0009476723,0.001025102,0.0005785396,0.001548722,0.0009781981,0.0004482222,0.002733215,0.0007369902],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008202372,"about_ca_system_score_gemma":0.002040467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001034975,"about_ca_topic_score_gemma":0.00176069,"domain_scores_codex":[0.9990514,0.0005418515,0.00004872684,0.0001626871,0.00007133322,0.0001240232],"domain_scores_gemma":[0.9988347,0.0002163835,0.0001612418,0.0001128123,0.00006615865,0.0006087366],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7482249,0.1197733,0.02045923,0.0006279188,0.001005737,0.0004923529,0.0006317468,0.002198124,0.04763545,0.0001773036,0.001684655,0.05708925],"study_design_scores_gemma":[0.4181496,0.5595313,0.01690612,0.00001763081,0.0002922371,0.0003051357,0.0000703943,0.0007982465,0.002613968,0.0000605707,0.001231172,0.00002358833],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995838,0.0008126392,0.0003659409,0.0001746244,0.00005762533,0.001839217,0.0002901008,0.00003840776,0.0005834515],"genre_scores_gemma":[0.9935517,0.0007904015,0.001251118,0.0003932373,0.0001653942,0.001948007,0.0008990379,0.00001940154,0.0009817909],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002974915,"threshold_uncertainty_score":0.015733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04924521051634979,"score_gpt":0.4041349497652443,"score_spread":0.3548897392488946,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}